Processed ECM Graft Materials Selective Component Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical graft materials derived from extracellular matrix (ECM) face challenges in selectively retaining beneficial components like growth factors and proteoglycans while removing undesired components such as native lipids, nucleic acids, and immunoglobulin A, which can affect their bioactivity and biocompatibility.
Innovation Solution
A processed ECM material is developed that retains collagen and non-collagen components, with low levels of undesired components like native lipids, nucleic acids, and immunoglobulin A, using methods such as treatment with dilute ionic detergent solutions, basic solutions to solubilize DNA, and organic solvents to reduce lipid content, while maintaining significant levels of growth factors and glycosaminoglycans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ECM material is subjected to a battery of manipulations to remove undesired components, then the levels of undesired components (native lipids, nucleic acids, immunoglobulin A) are reduced, but the desirable components (growth factors, cell adhesion proteins, proteoglycans) are also damaged or lost
Solution Approach 1:
The processing is divided into distinct sequential stages: (1) detergent treatment to remove immunoglobulins and lipids, (2) basic solution treatment to remove nucleic acids, and (3) organic solvent treatment to remove remaining lipids. Each stage targets specific undesired components while preserving desirable bioactive components through controlled exposure conditions.
Solution Approach 2:
The patent employs controlled parameter changes in each processing stage, including specific detergent concentrations (0.1-10% w/v), pH levels (10-14 for basic solutions), temperatures (4-37°C), and exposure times. These parameter optimizations enable selective removal of undesired components while maintaining the integrity and bioactivity of desirable components like growth factors and proteoglycans.
2Object-affected harmful factors
If ECM material undergoes extensive processing to achieve high sterility and biocompatibility, then immunogenicity is reduced, but the complexity of the manufacturing process increases
Solution Approach 1:
The processing protocol uses a universal sequence of treatments (detergent → basic solution → organic solvent) that simultaneously achieves multiple objectives: removal of immunoglobulins, lipids, and nucleic acids; reduction of immunogenicity; and preservation of bioactive components. This multi-functional approach simplifies manufacturing by consolidating multiple purification goals into a single integrated process.
Solution Approach 2:
The patent introduces intermediary substances and conditions to facilitate component separation: detergents as intermediaries to solubilize and remove immunoglobulins and lipids, basic solutions as intermediaries to solubilize nucleic acids, and organic solvents as intermediaries to extract remaining lipids. These intermediaries enable selective removal of undesired components without directly damaging desirable bioactive molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The resulting medical graft material exhibits enhanced angiogenic properties, improved biocompatibility, and reduced immunogenicity, making it suitable for various medical applications with controlled levels of bioactive components.
Implementation Method 1
treating the ECM material with a dilute ionic detergent solution to disrupt cell and nuclear membranes, and with a basic solution to solubilize and remove DNA and other nucleic acid materials
Implementation Method 2
with a basic solution to solubilize and remove DNA and other nucleic acid materials
Implementation Method 3
treating the ECM material with an organic solvent to remove lipids from the material
Implementation Method 4
with an oxidizing disinfectant solution, e.g. containing a peroxy compound, to disinfect the material
Data Source
AI summary
Described are medical graft materials and devices having improved properties relating to their component profiles.